Granata Bio Completes Screening in Phase III GRACE Study of GB-hMG
Pivotal IVF study advances into pregnancy follow-up, with the first GRACE baby expected by year-end BOSTON, Oct. 22, 2026 /PRNewswire/ -- Granata Bio Corporation, a biopharmaceutical company dedicated to advancing reproductive medicine, today announced the completion of screening in its...
Covered in this story
Call it yourself
No calls on $III yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Information Services Group Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.